New Technology Development Through Joint Research and Expansion into Healthcare
First written in FY2017. 17 of 20 entries say "Restated". Latest entry: FY2025.
0 other companies' latest entry also says "Other".
- FY2025Increase in R&D ExpenditureAnnual report
「As a result of these initiatives, total research and development expenses for the consolidated fiscal year amounted to ¥181 million.」
Continuing new technology development through joint research with companies, universities and others, with research and development expenses increasing from ¥153 million in the previous fiscal year to ¥181 million. - FY2023RestatedAnnual report
「Accordingly, our group is developing new technologies through joint research with companies, universities and others in several business areas, including healthcare. As a result of these initiatives, total research and development expenses for the consolidated fiscal year amounted to ¥153 million.」
Continuing new technology development through joint research with companies, universities and others, with annual research and development expenses amounting to ¥153 million. - FY2023-Q1RestatedAnnual report
「Total research and development expenses for the cumulative consolidated first-quarter period were ¥33 million.」
Continuing research and development activities, with research and development expenses of ¥33 million disclosed for the cumulative first-quarter period. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the cumulative consolidated nine-month period were ¥51 million.」
Continuing research and development activities, with research and development expenses for the cumulative consolidated nine-month period amounting to ¥51 million. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the cumulative consolidated six-month period were ¥32 million.」
Continuing research and development activities, with research and development expenses of ¥32 million disclosed for the cumulative consolidated six-month period. - FY2021RestatedAnnual report
「Accordingly, our group is developing new technologies through joint research with companies, universities and others in several business areas, including healthcare. As a result of these initiatives, total research and development expenses for the consolidated fiscal year amounted to ¥51 million.」
Continuing new technology development through joint research with companies, universities and others, with annual research and development expenses of ¥51 million. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the cumulative consolidated nine-month period were ¥34 million.」
Continuing research and development activities, with research and development expenses of ¥34 million disclosed for the cumulative consolidated nine-month period. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the cumulative consolidated six-month period were ¥22 million.」
Continuing research and development activities, with research and development expenses of ¥22 million disclosed for the cumulative consolidated six-month period. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the cumulative consolidated first-quarter period were ¥10 million.」
Continuing research and development activities, with research and development expenses of ¥10 million disclosed for the cumulative consolidated first-quarter period. - FY2020-Q3RestatedAnnual report
「Total research and development expenses for the cumulative consolidated nine-month period were ¥40 million.」
Continuing research and development activities, with research and development expenses of ¥40 million disclosed for the cumulative consolidated nine-month period. - FY2020-Q2RestatedAnnual report
「Total research and development expenses for the cumulative consolidated six-month period were ¥25 million.」
Continuing research and development activities, with research and development expenses of ¥25 million disclosed for the cumulative consolidated six-month period. - FY2020-Q1RestatedAnnual report
「Total research and development expenses for the cumulative consolidated first-quarter period were ¥14 million.」
Continuing research and development activities, with research and development expenses of ¥14 million disclosed for the cumulative consolidated first-quarter period. - FY2019-Q3RestatedAnnual report
「Total research and development expenses for the cumulative consolidated nine-month period were ¥66 million.」
Continuing research and development activities, with research and development expenses of ¥66 million disclosed for the cumulative consolidated nine-month period. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the cumulative consolidated six-month period were ¥38 million.」
Continuing research and development activities, with research and development expenses of ¥38 million disclosed for the cumulative consolidated six-month period. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the cumulative consolidated first-quarter period were ¥20 million.」
Research and development expenses of ¥20 million were disclosed for the cumulative consolidated first-quarter period. - FY2018RestatedAnnual report
「Our mission is to contribute to realizing the future society enabled by future mobile devices. During the consolidated fiscal year, our research and development activities focused on developing new technologies through joint research with companies, universities and the National Institute of Advanced Industrial Science and Technology, among others, and on initiatives to expand healthcare services, in order to continue providing high-value-added services supported by customers over the long term.」
Continued new technology development through joint research and expansion of the healthcare sector, with research and development expenses of ¥103 million for the year. - FY2018-Q3RestatedAnnual report
「Total research and development expenses for the cumulative consolidated nine-month period were ¥75 million.」
Research and development expenses of ¥75 million were disclosed for the cumulative consolidated nine-month period. - FY2018-Q2AdvancedAnnual report
「This is to promote collaboration aimed at expanding the adoption of cloud-based electronic medical records. Additional voting rights acquired on the business combination date 44.31% Voting rights after acquisition 50.86% Goodwill recognized ¥811.681 million Amortization method and period Straight-line amortization over 5 years」
By additionally acquiring shares in 株式会社クリニカル・プラットフォーム, the voting interest was raised to 50.86% and the company became a consolidated subsidiary, giving concrete form to collaboration aimed at expanding the adoption of cloud-based electronic medical records. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the cumulative consolidated first-quarter period were ¥40 million.」
Research and development expenses of ¥40 million were disclosed for the quarter. - FY2017First statedAnnual report
「We are engaged every day in initiatives to develop new technologies through joint research with companies, universities and the National Institute of Advanced Industrial Science and Technology, among others, and to expand our healthcare services. Total research and development expenses for the consolidated fiscal year were ¥264 million.」
Pursuing new technology development through joint research with companies, universities and the National Institute of Advanced Industrial Science and Technology, among others, and expanding the healthcare services sector, with research and development expenses of ¥264 million recorded.